FDA Approves Generic Formulation of Mesna Injection

Yael Waknine

April 21, 2010

April 21, 2010 — The US Food and Drug Administration (FDA) has approved a generic formulation for mesna injection (Sagent Pharmaceuticals, Inc, and Strides Arcolab, Ltd; Mesnex, Baxter International), a prophylactic agent used to reduce the incidence of ifosfamide-induced hemorrhagic cystitis.

The completely latex-free product will be available in 1 mg/10 mL multidose vials, sold singly and in packs of 10.

Mesna injection also features Sagent's proprietary PreventIV Measures packaging and labeling, which is designed to help prevent medication errors by differentiating drugs and doses, using unique label and carton designs, cap and label colors, bar coding, and other features.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: